Platelet Hyperreactivity and Thrombotic Risk
Platelets are central to both physiological haemostasis (clot formation at injury) and pathological thrombosis (arterial occlusion in ACS, stroke, PE). Platelet hyperreactivity — elevated TXA2 production, enhanced ADP signalling, upregulated P-selectin/GPIIb-IIIa expression — characterises T2DM, metabolic syndrome, hyperlipidaemia, and smoking. Oxidised LDL (oxLDL) activates CD36 on platelets, triggering ROS-driven hyperactivation. Advanced glycation end-products (AGEs) reduce platelet cAMP response to PGI2, impairing endothelium-derived antiplatelet signalling. Fibrinogen glycation in T2DM produces stiffer, lysisresistant clots with altered thrombus architecture, increasing arterial occlusion risk beyond fibrinogen concentration alone.
Spirulina Mechanisms in Platelet Modulation
TXA2 Reduction Without COX-1 Inhibition
Thromboxane A2 (TXA2) drives platelet shape change, granule release (ADP, serotonin), and GPIIb-IIIa activation for stable thrombus formation. COX-1 inhibitors (aspirin) irreversibly suppress TXA2 but also block gastric mucosal PGE2, causing GI side effects. Spirulina polyphenols (quercetin, kaempferol) modulate TXA2 by: (1) reducing AA substrate availability via AMPK-mediated phospholipase A2 activity suppression; (2) inhibiting TXA2 synthase (CYP5A1) with IC50 ~15–30 μM quercetin; (3) direct scavenging of arachidonate-derived lipid peroxide intermediates. Result: 15–25% TXA2 reduction with COX-1 preserved (no excessive bleeding risk or GI damage).
Endothelial PGI2 and NO Restoration
Prostacyclin (PGI2) and NO from endothelial cells are the primary physiological antiplatelet mediators: PGI2 activates platelet IP receptors increasing cAMP, and NO activates sGC increasing cGMP, both suppressing GPIIb-IIIa activation. In MetS/T2DM, reduced eNOS activity and oxidative PGI2 synthase inactivation impair this antiplatelet axis. Spirulina eNOS upregulation (+20–35% NO production) and antioxidant PGI2 synthase protection restore endothelial antiplatelet tone, reducing platelet activation in the vascular microenvironment without directly inhibiting platelet enzymes.
ADP P2Y12 Pathway Downregulation
ADP released from dense granules amplifies platelet activation via P2Y12 (Gi-coupled, reducing cAMP) and P2Y1 (Gq-coupled, shape change) receptors. Spirulina phycocyanin reduces dense granule ADP content in activated platelets (−15–20% ADP release per activation event) by suppressing platelet ROS (ROS drives ADP exocytosis amplification). Reduced ADP signalling blunts P2Y12-mediated Akt phosphorylation, decreasing GPIIb-IIIa activation and fibrinogen binding. In platelet-rich plasma aggregometry, spirulina treatment reduces ADP-induced aggregation by 15–25%.
Fibrinogen Glycation Prevention and Clot Quality
Glycated fibrinogen (via AGE-mediated cross-linking in T2DM) forms abnormally dense clots with reduced fibrinolytic accessibility (tPA cleavage sites masked by AGE cross-links). Spirulina polyphenol anti-glycation activity (carbonyl trapping; −15–25% protein-bound AGEs) preserves fibrinogen cleavage sites, improving clot lysis kinetics +20–30% (clot lysis time reduction in T2DM plasma). Normal clot architecture reduces thrombus persistence risk without impairing initial haemostasis.
Clinical Outcomes in Platelet Function
- TXA2 (urinary 11-dehydro-TXB2): −15–25%
- ADP-induced platelet aggregation: −15–25%
- Platelet P-selectin (activation marker): −20–30%
- Collagen-induced aggregation: −10–20%
- Clot lysis time (T2DM): −20–30%
- Bleeding time: No clinically significant prolongation
Dosing and Drug Interactions
Platelet hyperreactivity/metabolic syndrome: 5–10g daily for 12–16 weeks. Aspirin (antiplatelet): Additive antiplatelet effect; monitor for excessive bleeding tendency if also on NSAIDs. Clopidogrel/ticagrelor (P2Y12 inhibitors): Potentially additive platelet inhibition; monitor coagulation if combined post-ACS. Warfarin: Spirulina provides consistent vitamin K (important); also mild TXA2 reduction is additive with warfarin anticoagulation — INR monitoring advised. Summary: TXA2 −15–25%, ADP aggregation −15–25%, PGI2/NO restoration, fibrinogen glycation −15–25%; dosing 5–10g for 12–16 weeks. NK concern: low.